China-focused venture funds are finding it increasingly difficult to raise funds from Western investors due to rising geopolitical tensions and a lacklustre recovery in Asia’s biggest economy, some of the top players in the industry are warning.
Steven Wang, a Chinese biotech investor who manages some $2.6 billion, is among those sounding the alarm.